Angeles Estellés, PH.D.

Angeles Estellés, Ph.D. is an Associate Director and leads Protein Sciences in the Preclinical group at Link Cell Therapies. She has over 20 years of experience in antibody discovery and development for diverse clinical applications. During her tenure at Trellis Bioscience and under her leadership, a monoclonal antibody disrupting bacterial biofilms was discovered from human blood. This monoclonal antibody, TRL1068, is currently in a Phase I trial for treatment of prosthetic joint infections. She also worked on designing and testing nanoparticles, both cell-derived and synthetic, for targeted delivery of therapeutic agents.

Angeles obtained her B.S. in Pharmacy from the University of Valencia, Spain, and her Ph.D. from the University of Alicante, also in Spain. She then pursued post-doctoral training at the Mass General Hospital, Collège de France (Paris), and Stanford University.

Angeles has co-authored more than 15 scientific publications and is an inventor on 10 patents.